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Purpose: Guidelines recommend that genetic reports should be
clear to nonspecialists, including patients. We investigated the
feasibility of creating reports for cystic fibrosis carrier testing
through a rapid user-centered design process that built on a
previously developed generic template. We evaluated the new
reports’ communication efficacy and effects on comprehension
against comparable reports used in current clinical practice.
Methods: Thirty participants took part in three rounds of
interviews. Usability problems were identified and rectified in each
round. One hundred ninety-three participants took part in an
evaluation of the resulting reports measuring subjective compre-
hension, risk probability comprehension, perceived communication
efficacy, and other factors, as compared with standard reports.
Results: Participants viewing the user-centered reports rated them
as clearer, easier to understand, and more effective at commu-
nicating key information than standard reports. Both groups ended
up with equivalent knowledge of risk probabilities, although we
observed differences in how those probabilities were perceived.
Conclusion: Our findings demonstrate that by starting with a
patient-friendly generic report template and modifying it for
specific scenarios with a rapid user-centered design process, reports
can be produced that are more effective at communicating key
information. The resulting reports are now being implemented into
clinical care.
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019-0649-0
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INTRODUCTION
Genetic and genomic testing is becoming increasingly widely
available due to falling costs of testing, new referral pathways,
increased integration of such testing into mainstream clinical
practice, and other initiatives such as the National Health
Service (NHS) Long Term Plan and the Improving Outcomes
through Personalised Medicine effort in the United King-
dom.1 As access to such services expands, nonspecialist
clinicians are increasingly tasked with explaining the results of
these tests to patients. In some cases, patients may be faced
with the prospect of interpreting reports themselves without
guidance. For example, patients in some countries can obtain
copies of their test results directly from testing laboratories.2
Research suggests that even clinicians have difficulties
understanding genetic reports,3,4 and many researchers have
recognized the need for clearer reports in light of variability
among individuals in numeracy, health literacy, and genetic
literacy.2,5,6 Guidelines state that reports should be clear and
comprehensible to nonspecialists, and provide some guidance
on how to achieve this.2,7–14 Despite widespread adoption of
some guidelines, such as those of the American College of
Medical Genetics and Genomics (ACMG),7 studies investi-
gating patients’ and nonspecialists’ satisfaction and percep-
tions find that existing reports leave substantial room for
improvement.4,15–17 Genomic reports are especially challen-
ging due to lack of standardization18,19 and the complexity
and uncertainty of the information involved.20
There have been attempts to make the interpretation of
laboratory reports clearer to nonspecialist clinicians,16,21–25
but far fewer to make them clearer to patients. In 2014, Haga
et al.2 noted that “only one study has described efforts to
develop a patient-friendly pathology report” (p. 4). There
have since been some efforts to make genetic or genomic test
reports more patient-friendly,2,14,26–30 including in the direct-
to-consumer (DTC) industry.5,30 However, work of this kind
still appears rarely outside the DTC space, and there has been
little published (or made publicly available) about the
development of DTC reports. There are therefore few
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examples to guide the design and evaluation of a patient-
friendly genetic report.
In industry, it is common for new products to be developed
via a user-centered design31,32 approach whereby changes are
made in an iterative process, taking into account the context in
which the product will be used, key requirements, and feedback
from users. Typically, multiple rounds of evaluation are
conducted, monitoring metric(s) of interest (e.g., number and
severity of usability issues, time required for users to accomplish
a task, etc.) to assess what changes are needed. The iterative
process continues until some stopping criterion is reached.
With rare exceptions,25,28 user-centered design is not
generally used as a guiding framework in the context of
noncommercial genetic report development. Our aim was to
determine whether such a process could be used to efficiently
produce genetic report templates suitable for implementation.
If such reports could be shown to communicate more
effectively to laypersons, this would suggest a reasonable,
cost-efficient approach that could be emulated by others.
Our approach was to split the design phase into two. In a
first stage, patients, nonspecialist clinicians and genetic testing
experts participated in the development of a report template
for a fictional genetic condition. This work (submitted for
publication) resulted in a generic template that could be
adapted to specific use cases. We chose cystic fibrosis (CF)
carrier testing as our specific use case as primary care
physicians were being directed to order CF tests (and hence
receive and communicate results) in our local health-care
region. There was therefore a need to ensure that reports
from such testing were clear to nonspecialist readers. Our
study provides preliminary findings regarding benefits and
limits of what can be expected from a design process of
this kind.
MATERIALS AND METHODS
One design feature of the generic template was to accom-
modate the needs of both genetic specialists and nonspecia-
lists (including patients) by separating sections containing
technical information from those in “plain English.” There-
fore, our reports had both a “patient-centered” page and a
“clinician-centered” page, with the second page intended for
health professionals.
Five two-page draft reports were developed representing
common scenarios for CF carrier testing, where the reasons
for referral were the following: partner heterozygous for
p.Phe508del (positive and negative); familial p.Phe508del
(positive and negative); and family history (unknown variant),
negative report only. Reasons for referral were stated in
simpler language on the patient-centered page of each report.
Our initial reports were developed on the basis of our
previously designed generic report template, with input from
members of a working group who produced recommendations
based on a revision of the Association for Clinical Genomic
Science general reporting guidelines. This group included
members of the Regional NHS Clinical Genetics Laboratory in
Cambridge, clinical geneticists, genetic counselors, National
External Quality Assessment Service members, and other
experts in the reporting of genetic test results.
User-centered testing can take a formative or summative
approach. Formative testing is conducted iteratively while a
product is still in development, whereas summative testing is
done once the stopping criterion has been met and the design
finalized. Their goals differ accordingly: whereas “formative
testing focuses on identifying ways of making improvements,
summative testing focuses on evaluating against a set of
criteria”.33 All five reports were subject to formative testing,
and two were selected for summative testing, namely those
having “partner heterozygous for p.Phe508del” as the reason
for referral (Figs. S1, S2; sample patient-centered page in
Fig. 1). Corresponding anonymized “standard” report tem-
plates currently in use were obtained from Yorkshire and
North East Genomic Laboratory Hub Central Laboratory to
act as a control comparison (Figs. S3, S4), with permission.
Information that could have been used to identify the
laboratory that the templates came from was fictionalized.
Informed consent was obtained from all participants. This
study received ethical approval from the Cambridge Psychol-
ogy Research Ethics Committee (PRE.2018.077).
User-centered design process
Interviews
Three rounds of semistructured interviews were conducted
over Skype with a convenience sample of 30 volunteers
recruited from the Cambridge Rare Disease Network,
individuals who had participated in previous studies, and
researcher contacts. Twelve, eight, and ten volunteers
participated in each round, respectively. Volunteers were
compensated with Amazon vouchers for £10. Interviews
included questions pertaining to communication efficacy and
subjective comprehension (e.g., questions about reports’
appearance, structure, confusing language, etc.), objective
comprehension, and actionability. Demographic information
for participants in each round is summarized in Table S1.
Formative evaluation
The primary goal of the formative evaluation was to identify
and address the most serious usability problems with the
reports, borrowing the definition of Lavery et al.:34 “an aspect
of the system and/or a demand on the user which makes it
unpleasant, inefficient, onerous or impossible for the user to
achieve their goals in typical usage situations.” Given that
typical goals when receiving a genetic report are to (1)
understand the contents and (2) to take appropriate next steps
if necessary (or to advise the patient of appropriate next
steps), we treated as usability problems issues that caused
confusion, left participants with incorrect impressions,
generated unnecessary anxiety, or decreased the odds that a
participant would be able to get the assistance they needed to
take appropriate next steps. After rounds 2–3, interviewer
notes and partial transcriptions of participants’ answers to
interview questions were reviewed and coded in MaxQDA to
identify and evaluate the most significant problems, highlight
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Fig. 1 Patient-friendly page of user-centered “Positive/Partner p.Phe508del” report.
RECCHIA et al ARTICLE
GENETICS in MEDICINE | Volume 22 | Number 2 | February 2020 355
cases of poor comprehension, and assess the degree to which
the reports met participants’ information needs. Full coding
and partial transcription from interview recordings were
completed post hoc for round 1, but interviewer notes were
reviewed and usability problems were enumerated and
corrected prior to round 2 nevertheless. Our stop criterion
for how many rounds of interviewing to conduct was that by
the final round, no major usability problems should remain.
Major usability problems are those for which “the user will
probably use or attempt to use the product, but will be
severely limited in his or her ability to do so”;35 we considered
these to include issues that could leave recipients with a
serious misconception.
Because we ultimately wished to run a summative
evaluation focusing on subjective comprehension, risk prob-
ability comprehension, and communication efficacy, we
categorized participant answers to questions intended to
highlight usability issues that might affect these constructs in
particular, as well as more exploratory constructs of interest
(e.g., actionability, the degree to which “consumers of diverse
backgrounds and varying levels of health literacy can identify
what they can do based on the information presented”36).
These questions were asked to help determine whether there
were problems in any of these domains so severe as to
constitute a major usability problem.
Summative evaluation
Interviews were followed by an experiment in which
participants were given either the new (2-page) user-
centered report or a standard (1-page) report currently in
clinical use (and representative of standard practice). Our
approach was to provide participants with the entire user-
centered report, but to ask questions specific to the first page
of the report to ensure that the patient-facing page was the
one being evaluated. After receiving the participant informa-
tion sheet, a consent form, and background information about
cystic fibrosis, study participants were presented with a
clinical scenario in which a hypothetical John and Jane Doe
are thinking about starting a family. Neither has cystic
fibrosis, but CF runs in Jane’s family and she is known to be a
carrier, so John’s general practitioner (GP) has advised him to
have a carrier test to inform the couple’s family planning
decisions. Participants were then shown a copy of “John’s
report,” a report filled in with fictional information about Mr.
Doe, and asked to read it carefully. The report shown was
either one of the standard reports described earlier, or one of
the new user-centered reports. The evaluation therefore had a
2 × 2 factorial between-participants design with two levels of
design (standard and user-centered) and two levels of test
result (positive and negative). Afterward, participants com-
pleted a questionnaire collecting outcome measures. On every
questionnaire page, text stated “Please answer the following
based on what you have learned from the first page of the
report. To take another look at it, you may click here”;
clicking brought up the first page of the report. Note that
basic background information about cystic fibrosis was
provided to bring the experimental scenario closer to a
typical real-world scenario. This was not done within the
reports themselves, as in the real world a couple with CF in
one partner’s family would typically be aware of what CF is,
particularly after meeting with a GP and being referred for
testing.
Key outcomes were subjective comprehension, risk
probability comprehension, and communication efficacy
Subjective comprehension was assessed by asking “How well
did you understand the information in the first page of the
report?” and “How clear is the information on the first page of
the report?” on a seven-point scale ranging from 1 (“not at
all”) to 7 (“completely”). Risk probability comprehension was
assessed by tallying the number of risk probability compre-
hension questions answered correctly out of seven presented,
counting responses within ±1% of the correct answer as
“correct.” An investigator blinded to condition converted
free-text responses to numbers. Communication efficacy was
assessed using a version of the 18-item questionnaire
developed by Scheuner et al.,16 modified so as to be
appropriate for laypersons rather than clinicians (Table 1).
A power analysis suggested 192 participants were required to
achieve 80% power to detect an effect size f of 0.25 with intent
to test main effects and two-way interactions via analysis of
variance (ANOVA). Alpha was adjusted to 0.01, two-tailed,
permitting us to look for differences in the three key outcomes
described earlier at an α of 0.05 with adjustment for multiple
hypothesis testing. Normality of residuals was assessed using
the Shapiro–Wilk test (α= 0.05).
ANOVA is fairly robust to violations of normality, but for
severe violations nonparametric alternatives are sometimes
applied. For example, the Mann–Whitney test compares the
mean ranks of two samples, where the rank of a value is
determined by ranking all values from low to high regardless
of sample. Power analysis indicated that if this were used to
compare the user-centered and standard reports on any of our
key dependent variables, 192 participants would yield 78%
power to detect a medium-sized effect (d= 0.5, α= 0.01). The
Scheirer–Ray–Hare extension of the Kruskal–Wallis test37 is a
nonparametric ANOVA alternative based on ranks rather
than means; 192 participants would provide 78% power to
detect medium-sized main effects (f= 0.25, α= 0.01).
Forty-eight participants were randomized by the Qualtrics
survey distribution software to each combination of design
(standard and user-centered) and test result (positive and
negative), excepting positive user-centered, which had 49 due
to a glitch with Prolific. “Difficult” risk probability compre-
hension questions always followed “easy” questions, but the
order in which questions were presented was otherwise
counterbalanced by question type (Table 2). Our minimum
acceptable goal for the evaluation was to outperform the
standard template on at least one key outcome without being
inferior on the other two, although we hoped to outperform it
significantly on all measures. Tests were two-sided with
Bonferroni correction for multiple hypothesis testing.
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Measures of central tendency reported in “Results” are means,
unless otherwise stated.
A secondary goal was to achieve superiority on at least one
measure (without being inferior on any measure), out of all
measures recorded. This included not only key outcomes, but
also five exploratory measures: trust, actionability, risk
probability interpretation, visibility of result summary, and
ease of understanding the result summary. Trust was assessed
by asking “How much do you trust the information in the first
page of the report?” on a 7-point scale from 1 (“not at all”) to
7 (“completely”), and five questions related to actionability
were included (Table 1). Two risk probability interpretation
questions were included—“Is John a carrier of cystic fibrosis?”
and “If John and Jane have a child, will the child have cystic
fibrosis?”—with multiple-choice answers (definitely not,
unlikely, likely, and definitely). This provides insight into
how people understand the numbers, but we had no goal
beyond ensuring that viewers of positive reports did not
conclude that the couple would “definitely” or “definitely not”
have a child with CF, and that viewers of negative reports did
not conclude that the couple would “likely” or “definitely”
have a child with CF. This is because there is no right answer
with respect to whether a 25% chance of having a child with
cystic fibrosis feels “unlikely” or all too “likely.” Participants
were asked whether they had noticed the result summary (the
“Your Result” box for the user-centered report, or the
analogous “Summary” statement for the standard report)
and how easy the result was to understand (from 1 “not at all
Table 1 Scores for the standard and user-centered reportsa
Standard report User-
centered report
Mean SD Mean SD p value
Subjective comprehension, clarity, trust (7-point scale)
How well did you understand the information… 4.94 1.23 5.74 1.18 <0.001
How clear is the information… 4.65 1.31 5.78 1.20 <0.001
How much do you trust the information… 5.92 1.12 6.23 0.99 0.03
Communication efficacy (4-point scale modified from Scheuner et al.16)
How satisfied are you with…
The general format (look and feel)… 2.62 0.90 3.31 0.71 <0.001
The amount of information… 2.83 0.83 3.38 0.73 <0.001
The organization of the information… 2.68 0.88 3.29 0.71 <0.001
How easy is it to…
Find the test result… 2.67 0.95 3.35 0.78 <0.001
Find information…to help with decision making? 2.42 0.90 3.10 0.78 <0.001
Understand the language used… 2.35 0.88 3.25 0.78 <0.001
Understand the test result presented… 2.53 0.89 3.34 0.76 <0.001
Understand the interpretation of the test result… 2.56 0.90 3.13 0.80 <0.001
How effectively does the first page of the report…
Communicate the test result? 2.67 0.88 3.38 0.73 <0.001
Communicate what this test result means? 2.47 0.98 3.23 0.67 <0.001
Communicate the patient’s options (i.e., John’s options) having received this test result? 2.16 1.00 2.94 0.79 <0.001
Communicate the availability of information resources for the patient (i.e., John)? 1.98 0.96 2.95 0.86 <0.001
Communicate the availability of information resources for health professionals (i.e., John’s GP)? 2.10 0.92 2.87 0.82 <0.001
Inform medical decisions the patient (i.e., John) might have to make as a result of this test? 2.46 0.99 3.01 0.74 <0.001
Help you explain what the test result means to other people? 2.42 0.93 3.00 0.88 <0.001
Help you understand the medical issues relating to the result? 2.27 0.90 2.81 0.89 <0.001
Help you understand the genetic aspects of the result? 2.40 0.93 2.97 0.85 <0.001
Communicate any limitations of the test result? 1.83 0.83 2.69 0.96 <0.001
Actionability (7-point scale)
How clear are you about the next steps that you could take… 4.40 1.60 5.53 1.35 <0.001
Do you feel you would have the necessary information to decide what to do next… 4.26 1.71 5.21 1.52 <0.001
How certain are you about what you would do next… 4.49 1.75 5.62 1.32 <0.001
Do you feel you would have the necessary professional support to decide what to do next… 4.45 1.53 5.47 1.30 <0.001
How ready would you feel to take any next steps… 4.27 1.72 5.21 1.38 <0.001
aTo make the table more compact, ellipses (“…”) appearing in communication efficacy questions and subjective understanding/clarity/trust questions stand in for the
phrase “in the first page of the report” (“of the first page of the report,” communication efficacy question 1). Ellipses appearing in actionability questions stand in for
the phrase “if you had received this report in real life.”
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easy” to 7 “very easy”). Finally, subjective numeracy38 was
collected, as well as demographic information.
RESULTS
Formative evaluation
Quantitative summaries of participant responses to questions
relating to subjective comprehension, risk probability com-
prehension, communication efficacy, and actionability are
provided in Figs. S5–S9 and Table S3. Answers to these
questions suggested adequate comprehension of the version 3
reports, at least in our small sample of ten participants
(Table S3). A summary of changes made after each round of
testing is available in Tables S4 and S5, and qualitative
description of usability problems in each round and severity
classifications are given in Table S6, with nothing rising to the
level of a major usability problem by the final round.
Formative evaluation was therefore stopped at this point
and a summative evaluation was conducted for the version 3
partner reports. A full analysis of all substantive participant
comments is beyond the scope of this paper, but a few
examples of how specific usability issues led to specific
changes are detailed in Table S7.
One issue noted during round 3 was that multiple
participants commented that they had not noticed the result
summary box on their first read-through. This did not rise to
the level of a usability problem as these participants all read
and understood the description of the result in the “What
This Result Means For You” section, but it was of sufficient
concern that visibility of result summary was added to the
summative evaluation as an exploratory measure.
Summative evaluation
One hundred ninety-three participants were paid £1.96/
person to complete the study via Prolific Academic; demo-
graphic characteristics appear in Table S2. Due to violations
of normality, Mann–Whitney U-tests were used rather than
ANOVAs, comparing mean ranks between the two
conditions.
Subjective comprehension was higher for the user-centered
(UC) reports, whether participants were asked about
understanding (MUC= 5.74, SDUC= 1.18, Mstandard= 4.94,
SDstandard= 1.23, U= 2896, p < 0.001, d= 0.7) or clarity
(MUC= 5.78, SDUC= 1.20, Mstandard= 4.65, SDstandard=
1.31, U= 2322, p < 0.001, d= 0.9). No differences were
observed in risk probability comprehension (MUC= 4.95,
SDUC= 2.30, Mstandard= 4.94, SDstandard= 2.31, U= 4618,
p= 0.9, d= 0.0), and item-wise chi-squared tests revealed
that no questions in Table 2 were answered correctly more
frequently in one condition than the other. Like Scheuner
et al.,16 we compared the mean total scores on communica-
tion efficacy, finding higher scores for the user-
centered reports (MUC= 3.11, SDUC= 0.56, Mstandard= 2.41,
SDstandard= 0.7, U= 2045, p < 0.001, d= 1.1). Item-wise
analyses found significant differences for each item in favor
of the user-centered reports, all p < 0.001 (Table 1). Analogous
U-tests comparing positive versus negative reports were
conducted, none of which found significant results.
User-centered reports trended slightly higher with
respect to trust (MUC= 6.23, SDUC= 0.99, Mstandard= 5.92,
SDstandard= 1.12, U= 3874, p= 0.03, d= 0.3), nonsignificant
after correction for multiple hypothesis testing. They were
Table 2 Measures of participant comprehension of risk probabilities
Question ID/
type and
difficulty
Question Answer format
Q1/Carrier
risk (easy)
What do you think the probability is that John is a carrier of cystic fibrosis? You can
indicate this probability as a percentage, or in another way if you prefer.
Free text
Q2/Carrier
risk (easy)
Please indicate the probability that John is a carrier of cystic fibrosis by dragging the slider
below.a
Probability slider from “0% chance” to
“100% chance”
Q3/Risk to
child (easy)
If John and Jane have a child, what do you think the probability is that the child will have
cystic fibrosis? You can indicate this probability as a percentage, or in another way if you
prefer.
Free text
Q4/Risk to
child (easy)
Please indicate the probability that the child will have cystic fibrosis by dragging the slider
below.a
Probability slider from “0% chance” to
“100% chance”
Q5/Risk to
child (hard)
Imagine that there are 1000 couples in exactly the same situation as John and Jane: that is
to say,
• one partner is a carrier (like Jane is), and
• the other partner has had the same test that John has had, and received the same result
as John did.
If each of these 1000 couples have one child, about how many of these 1000 children
would have cystic fibrosis?
If you aren’t sure, or if you think there are many possibilities, please make your best
guess as to the most likely number of children to have cystic fibrosis, from 0 to 1000.
Free text; single number expected
Q6/Risk to
child (hard)
[As above with “800” in place of “1000”] Free text; single number expected
Q7/Both risks •Which of the following possibilities is more likely?
• John Doe is a carrier of cystic fibrosis
• The first child of John and Jane Doe will have cystic fibrosis
Multiple choice:
• It’s more likely that John Doe is a carrier of
cystic fibrosis
• It’s more likely that the first child of John
and Jane Doe will have cystic fibrosis
• Both possibilities are equally likely
•Don’t know
aThe following text followed in both cases: “If you aren’t sure, please make your best guess. If you can’t mark exactly the probability you want using the slider, please
put it as close to that probability as you can.”
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reliably higher on actionability (MUC= 5.41, SDUC= 1.20,
Mstandard= 4.37, SDstandard= 1.47, U= 2733, p < 0.001, d=
0.8), with item-wise analyses favoring the new reports on
every question (Table 1). Surprisingly, 27% reported that they
had not noticed the result summary in the user-centered
reports versus 8% in the standard reports, X2(1, N= 193)=
10.1, p= 0.001. However, estimates of John’s probability of
being a carrier (Table 2, question 2) were no different,
suggesting that this information was clear even to those who
missed the summary (positive reports: median 100% both
conditions, MUC= 0.86, SDUC= 0.29, Mstandard= 0.80,
SDstandard= 0.32, U= 1170, p > 0.9, d= 0.2; negative reports:
median 1% both conditions, MUC= 0.07, SDUC= 0.16,
Mstandard= 0.07, SDstandard= 0.16, U= 1161, p > 0.9, d=
0.0). The user-centered reports’ result summaries were
also rated easier to understand, MUC= 6.05, SDUC= 1.33,
Mstandard= 5.00, SDstandard= 1.66, U= 2876, p < 0.001,
d= 0.7.
When estimating the probability that the first child would
have cystic fibrosis (Table 2, question 4), there were no
significant differences between levels of design for either
positive reports (median 25% both conditions; MUC= 0.31,
SDUC= 0.16, Mstandard= 0.33, SDstandard= 0.19, U= 1328,
p= 0.2, d=−0.2) or negative reports (median 1% both
conditions; MUC= 0.10, SDUC= 0.17, Mstandard= 0.06,
SDstandard= 0.11, U= 1100, p= 0.8, d= 0.3). Nevertheless,
responses to the risk interpretation questions suggested
possible differences in the interpretation of these numbers
(Fig. 2) for those who had been shown the positive reports,
with those who saw the user-centered positive report more apt
to say that a child of two carriers was “unlikely” to have cystic
fibrosis than those who saw the standard positive report, X2(1,
N= 97)= 7.8, p= 0.005. Overall performance with respect to
the goals of the evaluation is summarized in Table S8.
Despite the violations of normality, 2 × 2 ANOVAs crossing
design with test result as well as the Scheirer–Ray–Hare
extension of the Kruskal–Wallis test were also run on our key
dependent measures. In both cases the same main effects were
found, with no significant interactions.
DISCUSSION
Our findings suggest that by starting with a patient-friendly
generic report template and modifying it for a specific genetic
test with a rapid user-centered design process, reports can be
made that laypersons find significantly clearer, easier to
understand, and more effective at communicating key
information, including what they should do next (action-
ability). The improvements in actionability are particularly
encouraging, as several interview participants noted that it is
especially important that patients feel they understand “next
steps,” and that they feel they have adequate information and
support to make follow-up decisions. We also saw cautions
from the risk comprehension literature39 borne out in our
qualitative results (Table 3). Although we found no
differences in risk probability comprehension, performance
was near ceiling, with a median of 6 of 7 questions correct for
both the user-centered and standard reports. Furthermore,
combining user-centered testing with quantitative evaluation
led us to insights that would have been difficult to achieve
without both methods. For example, some individuals noted
that although they understood their results from reading the
text of the report, they had missed the summary box titled
40
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Co
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Definitely
not
Likely Definitely Don’t
know
Unlikely Definitely
not
Likely Definitely Don’t
know
Unlikely
Standard
Design
User-centered
“If John and Jane have a child, will the child have cystic fibrosis?”
Fig. 2 Responses given by participants who viewed reports with positive test results to the question “If John and Jane have a child, will the
child have cystic fibrosis?” When asked to produce the numeric probability that the first child would have cystic fibrosis (Table 2, Section 4), participants
who felt it was “likely” that the first child would have cystic fibrosis had mean estimates of 34% (SD= 21%) if they had seen the standard report, compared
with 31% (SD= 12%) if they had seen the user-centered report (no significant difference, U= 473, p= 0.7). Participants who felt it was “unlikely” that the
first child would have cystic fibrosis had mean estimates of 25% (SD= 0.4%) if they had seen the standard report, compared to 27% (SD= 14%) if they
had seen the user-centered report (no significant difference, U= 100, p= 0.4).
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“Your Result.” Therefore, we added a question investigating
this to our quantitative evaluation, which confirmed that 27%
of participants did not remember seeing this box. Thus, even
anecdotal evidence from small qualitative studies can generate
important hypotheses that can then be tested more rigorously.
One limitation of our formative evaluation was that
participants were overwhelmingly female (80%) and highly
educated (Table S1). Our summative evaluation sample had
similar biases (~69% female, ~56% university-educated), among
other differences from the UK population (Table S2). Although
subgroup analysis demonstrated that the benefits of our novel
templates were thankfully not restricted to women, nor to the
highly educated or highly numerate (Table S9), our develop-
ment process could have identified important issues more
quickly if we had solicited input from a more diverse group of
participants from the outset. Given this nonrepresentative
sample and the fact that it was more difficult to see the result
summary in our report than in the standard report, we have
made one additional change to address this, and are planning a
replication of our summative evaluation with this new report
using census-matched cross-stratified quota sampling.
Another drawback is that the use of a hypothetical scenario
with our testing group means that our results are less likely to
generalize than if they had been conducted as part of a clinical
study. (See Stuckey et al.,26 Williams et al.28 for examples of
patient-facing work that does not suffer from this limitation.)
Furthermore, this study was limited to a single autosomal
recessive condition. We have planned future research on
reports for BRCA1/BRCA2 testing, which will investigate
whether the benefits of this approach generalize to material
that is more challenging to communicate.
Overall, our experience demonstrated that a user-centered
approach can be extremely helpful in discovering and
rectifying usability problems with genetic reports. We hope
that this research illustrates how rapid user-centered design
can be used to develop more comprehensible and actionable
reports, and that building on templates developed via user-
centered design may be useful in developing patient-facing
materials more generally.
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Table 3 Recommendations and lessons learned
Topic Recommendation
Design Splitting the design process into two phases—one to
develop a generic template with key sections and
information that patients want from the results, and
one to populate that template with the specific
numbers and information for each type of test—may
provide an efficient way to produce large numbers of
report templates for medical test results.
Test with users: recommendations from the literature
should not be applied blindly. For example, although
there are good reasons to present risk figures in
multiple formats as a general rule, in our case including
“1 in 25 (4%)” and “1 in 4 (25%)” in close proximity
caused confusion. User testing permitted us to address
the issue in a way that allowed us to continue following
the recommendation but also eliminated the confusion.
Focus on recruitment of diverse representative end users
throughout the process. We benefited from multiple
perspectives of different user groups (health-care
providers, patients, and members of the public with
varying levels of experience of genetic testing), and
would have benefited from a more concerted effort to
recruit participants who were more diverse in other
ways (e.g., education).
Evaluation Following up on comments from interviews with a
larger sample size can be a useful way to determine
whether an offhand comment (“I don’t know how I
missed that!”) is indicative of a larger issue (27% of
participants indicating that they did not see the result
summary box).
Formative and summative evaluation both ought to be
applied to important patient-facing materials whenever
possible.
Vocabulary and
wording
When using vocabulary that implies a change in risk
(e.g., reduce/increase), the risks being compared must
be clearly described.
For patient-facing materials, “gene changes” is a poor
plain-English alternative to “variant,” as it sometimes
led to misinterpretations (e.g., “What does it mean by
no cystic fibrosis gene changes detected? Can genes
change throughout the life course or something? I
thought you’re kind of born with it or you’re not.”) In
our study, “alterations” seemed to be reasonably well
received and interpreted.
Prior literature39 has found that a quarter of people
incorrectly answer the question “Which of the following
numbers represents the biggest risk of getting a
disease? 1 in 100, 1 in 1000, or 1 in 10?”, not realizing
that a larger number in the denominator corresponds to
a smaller probability. A quote from one of our
participants suggested she had a similar
misapprehension (“less than 1 in 500 sounds less scary,
because then you can think, oh, it could be 400 or
200”). When presenting probabilities that are intended
to be compared with each other, keep denominators
constant to decrease the chances of misinterpretation,
i.e., compare 1 in 1000 with 6 in 1000 rather than
comparing 1 in 1000 with 1 in 167.
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